We are focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
[ Read more ]
MEI Pharma Announces $15.2 Million Registered Offering of Common Stock
[ April 5, 2013 ]
MEI Pharma Adds Tom Reynolds to Board of Directors
[ February 11, 2013 ]
Click here for our 2012 Annual Report